STAT-Dx obtains a EUR 20 million EIB loan facility under the InnovFin programme - Gilde Healthcare

STAT-Dx obtains a EUR 20 million EIB loan facility under the InnovFin programme

June 1, 2017

Malta

STAT-Dx

  • EUR 20 million EIB loan facility under the InnovFin programme to support medical diagnostics innovation in Spain
  • The EIB is providing STAT-Dx (STAT-Diagnostica & Innovation, S.L.), a Spanish company developing advanced molecular diagnostic systems to help combat meningitis and other infectious diseases, with a EUR 20 million loan facility.

The European Investment Bank (EIB), the EU bank, is supporting the improvement of infectious diseases diagnostics through a EUR 20 million loan agreement signed today with STAT-Dx (STAT-Diagnostica & Innovation, S.L), a Spanish start-up based in Barcelona developing a new molecular diagnostics device capable of identifying a wide range of infectious pathogens, such as meningitis, respiratory or gastro-intestinal infections in about one hour. STAT-Dx’s technology enables clinicians to test simultaneously for the presence or absence of multiple pathogens caused by or associated with specific syndromes, allowing faster diagnostics and improving survival rates in “near-to-care” environments such as intensive care units and emergency rooms.

The EIB loan was signed today at the EU Innovative Enterprise Summit held in Malta and attended by EIB Vice-President for Innovation Ambroise Fayolle. It will be drawn down in two tranches over a three-year period, with full repayment on the maturity date five years ahead. This agreement will serve to co-finance a three-year project aimed at enabling faster and more accurate diagnostics that will replace current complex protocols to obtain analytical results. The DiagCORE system developed by STAT-Dx is a cartridge based single-test solution. By providing instant available results this new technology will enable immediate and well informed medical decisions to be made. The CE-marking of DiagCORE with a respiratory panel application is planned by the end of 2017.

“We are pleased to have received this loan from the EIB, which brings together the strength of public and private financing to accelerate the development and commercialisation of novel diagnostic technologies,” said Jordi Carrera, Chief Executive Officer of STAT-Dx.

“The InnovFin Programme helps bridge an important gap for innovative companies like STAT-Dx, from early market introduction to commercialisation, which is key to fostering a strong and vibrant industry in Europe that can compete on the global stage.” Didier Le Normand, Chief Financial Officer of STAT-Dx added: “EIB joins as a new reputable financing partner to bring STAT Dx, alongside its strong and supportive shareholder base, additional resources for its next stage development”.

Innovation and skills are key ingredients for ensuring sustainable growth and creating high-value jobs. This is why the EIB is a major partner for projects that develop innovation and long-term competitiveness for a growing economy. In 2016, the EIB supported innovation and skills with EUR 13.5bn of financing.

More news

Boston Scientific to Acquire Nalu Medical

We are pleased to announce the strategic exit of our portfolio company Nalu Medical. Boston Scientific, a global leader in medical technology, has agreed to acquire Gilde Healthcare portfolio company Nalu Medical at a $600m valuation....
October 17, 2025

Gilde Healthcare company Tagworks Pharmaceuticals Announces CTA Authorization and Initiation of Phase 0/1 Clinical Trial for TGW211, a Radiopharmaceutical for the Treatment of HER2+ Tumors

TGW211 is a next-generation, first-in-class HER2-directed radioimmunoconjugate developed based on Tagworks’ proprietary Click-to-Release – bioorthogonal, in vivo click chemistry – linker platform TGW211 is designed to achieve strong tumor uptake with selective and rapid elimination...
October 15, 2025

Gilde Healthcare company SpyGlass Pharma’s Novel BIM-IOL System Demonstrated a Statistically Significant Reduction in Mean IOP at 24 Months

42% reduction in mean intraocular pressure (IOP) compared to baseline (p<0.0001) 100% of patients were off all topical IOP-lowering medications at 24 months 100% of treated patients achieved 20/30 or better Best Corrected Distance Visual...
October 14, 2025